Navann Ty
Stock Analyst at Exane BNP Paribas
(3.20)
# 2,567
Out of 4,696 analysts
39
Total ratings
55.6%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Downgraded: Hold | $15 → $14 | $13.76 | +1.74% | 6 | Apr 28, 2026 | |
| MDLN Medline | Initiated Coverage: Hold | $38 | $35.11 | +8.23% | 1 | Jan 12, 2026 | |
| NTRA Natera | Upgraded: Hold | $28 → $172 | $320.76 | -46.38% | 2 | Oct 27, 2025 | |
| GEHC GE HealthCare Technologies | Reiterated: Buy | $92 | $70.42 | +30.64% | 1 | Sep 10, 2025 | |
| PAHC Phibro Animal Health | Maintained: Hold | $24 → $37 | $38.37 | -3.57% | 2 | Sep 4, 2025 | |
| COO The Cooper Companies | Upgraded: Buy | $92 | $69.28 | n/a | 1 | Jul 22, 2025 | |
| KVUE Kenvue | Initiated Coverage: Hold | $28 | $18.75 | n/a | 1 | May 30, 2023 | |
| SKIN SkinHealth Systems | Upgraded: Hold | n/a | $0.675 | n/a | 2 | Mar 20, 2023 | |
| ABBV AbbVie | Initiated Coverage: Hold | $169 | $259.99 | n/a | 1 | Dec 8, 2022 | |
| EOLS Evolus | Initiated Coverage: Buy | $13 | $9.08 | n/a | 1 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $22 → $26 | $47.20 | n/a | 2 | Mar 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 → $11 | $16.63 | n/a | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $232 → $208 | $77.25 | n/a | 6 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $200 | $243.71 | n/a | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 → $42 | $23.91 | n/a | 6 | May 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36.12 → $51.40 | $9.01 | n/a | 3 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $10 | $36.19 | n/a | 1 | Apr 24, 2020 |
Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15 → $14
Current: $13.76
Upside: +1.74%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $35.11
Upside: +8.23%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28 → $172
Current: $320.76
Upside: -46.38%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $70.42
Upside: +30.64%
Phibro Animal Health
Sep 4, 2025
Maintained: Hold
Price Target: $24 → $37
Current: $38.37
Upside: -3.57%
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $69.28
Upside: n/a
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $18.75
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.675
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $259.99
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $9.08
Upside: n/a
Mar 22, 2022
Maintained: Hold
Price Target: $22 → $26
Current: $47.20
Upside: n/a
Mar 10, 2022
Maintained: Hold
Price Target: $16 → $11
Current: $16.63
Upside: n/a
Mar 9, 2022
Maintained: Hold
Price Target: $232 → $208
Current: $77.25
Upside: n/a
Oct 5, 2021
Initiated Coverage: Buy
Price Target: $200
Current: $243.71
Upside: n/a
May 17, 2021
Maintained: Buy
Price Target: $39 → $42
Current: $23.91
Upside: n/a
Mar 2, 2021
Maintained: Buy
Price Target: $36.12 → $51.40
Current: $9.01
Upside: n/a
Apr 24, 2020
Initiated Coverage: Hold
Price Target: $10
Current: $36.19
Upside: n/a